Scleroderma drug gets fast-tracked in the US
The US Food and Drug Administration (FDA) has granted Fast Track Designation for Certa Therapeutics’ investigational therapy FT011 for the treatment of systemic sclerosis (scleroderma). The Fast Track Designation was granted based on results of a Phase II study which indicated that treatment of scleroderma patients… Read More
